Frailty and checkpoint inhibitor toxicity in older patients with melanoma.

Cheryl P Bruijnen Josephine J KoldenhofRik J VerheijdenFrederiek van den BosMariëlle H Emmelot-VonkPetronella O WitteveenKarijn P M Suijkerbuijk

Published in: Cancer (2022)

Although frailty appears to be unrelated to the occurrence of severe irAEs, it is an indicator of irAE-related adverse sequelae, such as hospital admission. Screening for frailty can be of added value in the shared decision-making process for older patients who qualify for ICI treatment.

Keyphrases

community dwelling
emergency department
dna damage
risk assessment
healthcare
oxidative stress
physical activity
early onset
drug induced